Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jul 15, 2022; 14(7): 1252-1264
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1252
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1252
Figure 1 Online analysis of gene expression of claudin 18 and its effected survival in pancreatic cancer using the database.
A: Analysis of claudin18 expression in normal pancreatic tissue and pancreatic cancer using the TNMplot.com (https://tnmplot.com/analysis/) based on The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEX), and Gene Expression Omnibus (GEO) databases; B: Analysis of claudin18 expression in normal pancreatic tissue and pancreatic cancer using Xena (http://xena.ucsc.edu/compare-tissue/) based on TCGA and GTEX databases; C: Assessment of the claudin18 effect on survival in pancreatic cancer using KM plotter (https://kmplot.com/analysis/) based on GEO, European Genome-phenome Archive, and TCGA databases. HR: Hazard ratio.
- Citation: Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264
- URL: https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i7.1252